Transplant Drug Interactions and a Word of Caution for the HIV Provider. A Case Report.

Loading...
Thumbnail Image

Date

2018-04-05

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

98
views
73
downloads

Citation Stats

Abstract

Electronic medical record platforms fail to support provider alerts when a drug is discontinued. Protease inhibitors, often boosted by ritonavir or cobicistat, increase the serum concentration of calcineurin inhibitors. This case demonstrates acute liver transplant rejection in an HIV-positive recipient due to a failure to recognize the loss of protease inhibitor interaction with his immunosuppressive regimen.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.1093/ofid/ofy070

Publication Info

Hemmersbach-Miller, Marion, Carl L Berg, Julia A Messina and Cameron R Wolfe (2018). Transplant Drug Interactions and a Word of Caution for the HIV Provider. A Case Report. Open forum infectious diseases, 5(4). p. ofy070. 10.1093/ofid/ofy070 Retrieved from https://hdl.handle.net/10161/18164.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Berg

Carl Berg

Professor Emeritus of Medicine
Messina

Julia Antoinette Messina

Associate Professor of Medicine

I am a Transplant Infectious Diseases Physician who specializes in the care of immunocompromised patients including solid organ and bone marrow transplant recipients and patients with HIV. My research interests are in infections and clinical outcomes in patients with hematologic malignancies.

Wolfe

Cameron Robert Wolfe

Professor of Medicine

HIV infection, Transplant-related infectious diseases, general infectious diseases, Biological and Emergency Preparedness for hospital systems, influenza and respiratory viral pathogens


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.